ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer

Purpose: AT-rich interactive domain 1A (ARID1A) is commonly mutated in colorectal cancer, frequently resulting in truncation and loss of protein expression. ARID1A recruits MSH2 for mismatch repair during DNA replication. ARID1A deficiency promotes hypermutability and immune activation in preclinical models, but its role in patients with colorectal cancer is being explored. Experimental Design: The DNA sequencing and gene expression profiling of patients with colorectal cancer were extracted from The Cancer Genome Atlas and MD Anderson Cancer Center databases, with validation utilizing external databases, and correlation between ARID1A and immunologic features. IHC for T-cell markers was performed on a separate cohort of patients. Results: Twenty-eight of 417 patients with microsatellite stable (MSS) colorectal cancer (6.7%) had ARID1A mutation. Among 58 genes most commonly mutated in colorectal cancer, ARID1A mutation had the highest increase with frameshift mutation rates in MSS cases (8-fold, P < 0.001). In MSS, ARID1A mutation was enriched in immune subtype (CMS1) and had a strong correlation with IFNγ expression (Δz score +1.91, P < 0.001). Compared with ARID1A wild-type, statistically significant higher expression for key checkpoint genes (e.g., PD-L1, CTLA4, and PDCD1) and gene sets (e.g., antigen presentation, cytotoxic T-cell function, and immune checkpoints) was observed in mutant cases. This was validated by unsupervised differential expression of genes related to immune response and further confirmed by higher infiltration of T cells in IHC of tumors with ARID1A mutation (P = 0.01). Conclusions: The immunogenicity of ARID1A-mutant cases is likely due to an increased level of neoantigens resulting from increased tumor mutational burden and frameshift mutations. Tumors with ARID1A mutation may be more susceptible to immune therapy–based treatment strategies and should be recognized as a unique molecular subgroup in future immune therapy trials.

[1]  V. Balis,et al.  Diagnostic significance and prognostic role of the ARID1A gene in cancer outcomes (Review) , 2020 .

[2]  Kathleen R. Cho,et al.  Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. , 2020, The Journal of clinical investigation.

[3]  Mei Jiang,et al.  Procedural Requirements and Recommendations for Multiplex Immunofluorescence Tyramide Signal Amplification Assays to Support Translational Oncology Studies , 2020, Cancers.

[4]  T. Jiang,et al.  Pan-cancer analysis of ARID1A Alterations as Biomarkers for Immunotherapy Outcomes , 2020, Journal of Cancer.

[5]  C. Röcken,et al.  Intratumoral heterogeneity and loss of ARID1A expression in gastric cancer correlates with increased PD-L1 expression in Western patients. , 2019, Human pathology.

[6]  Jeffrey H. Chuang,et al.  Clinical and immunological implications of frameshift mutations in lung cancer. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  Xiaosheng Wang,et al.  ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer , 2019, Cells.

[8]  Z. Stadler,et al.  Immunotherapy in colorectal cancer: rationale, challenges and potential , 2019, Nature Reviews Gastroenterology & Hepatology.

[9]  M. Szewczuk,et al.  Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates , 2019, Journal of oncology.

[10]  Dakeun Lee,et al.  Functional loss of ARID1A is tightly associated with high PD‐L1 expression in gastric cancer , 2019, International journal of cancer.

[11]  P. Ulivi,et al.  Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine? , 2018, International journal of molecular sciences.

[12]  T A Chan,et al.  Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[14]  F. Meric-Bernstam,et al.  The characteristics of ARID1A mutations in colorectal cancer. , 2018 .

[15]  G. Mills,et al.  ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade , 2018, Nature Medicine.

[16]  L. Macconaill,et al.  Frameshift events predict anti-PD-1/L1 response in head and neck cancer. , 2018, JCI insight.

[17]  Ritika Kundra,et al.  Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. , 2018, Cancer cell.

[18]  I. Wistuba,et al.  Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues , 2017, Scientific Reports.

[19]  Nicolai J. Birkbak,et al.  Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. , 2017, The Lancet. Oncology.

[20]  A. Jazaeri,et al.  Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators , 2017, Front. Immunol..

[21]  Robyn L. Temple-Smolkin,et al.  Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. Park,et al.  ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice , 2016, Nature Genetics.

[23]  Eric S. Lander,et al.  Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma , 2016, Cell reports.

[24]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[25]  R. Xu,et al.  Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer. , 2014, World journal of gastroenterology.

[26]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[27]  Chichung Wang,et al.  Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. , 2014, Methods.

[28]  Kai Ye,et al.  MSIsensor: microsatellite instability detection using paired tumor-normal sequence data , 2014, Bioinform..

[29]  Tian-Li Wang,et al.  The emerging roles of ARID1A in tumor suppression , 2014, Cancer biology & therapy.

[30]  B. Clarke,et al.  ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas , 2014, Modern Pathology.

[31]  Swe Swe Myint,et al.  Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers , 2013, Nature Genetics.

[32]  Mauricio O. Carneiro,et al.  From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline , 2013, Current protocols in bioinformatics.

[33]  H. Morreau,et al.  Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer , 2013, Modern Pathology.

[34]  Jeffrey J Meyer,et al.  Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012. (5) , 2013 .

[35]  Jonathan R. Pollack,et al.  The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers , 2013, PloS one.

[36]  D. Reisman,et al.  Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity. , 2012, Experimental cell research.

[37]  S. Ishikawa,et al.  ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein–Barr virus infection and microsatellite instability , 2012, Virchows Archiv.

[38]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[39]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[40]  Bin Tean Teh,et al.  Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes , 2012, Nature Genetics.

[41]  Zhengyan Kan,et al.  Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer , 2011, Nature Genetics.

[42]  Tian-Li Wang,et al.  ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. , 2011, Cancer research.

[43]  Meng Li,et al.  Somatic Mutations in the Chromatin Remodeling Gene ARID1A Occur in Several Tumor Types , 2011, Human mutation.

[44]  Tian-Li Wang,et al.  Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.

[45]  So-jung Kim,et al.  A cooperative activation loop among SWI/SNF, γ‐H2AX and H3 acetylation for DNA double‐strand break repair , 2010, The EMBO journal.

[46]  G. Wani,et al.  Modulation of Nucleotide Excision Repair by Mammalian SWI/SNF Chromatin-remodeling Complex* , 2009, The Journal of Biological Chemistry.

[47]  B. Cairns,et al.  The biology of chromatin remodeling complexes. , 2009, Annual review of biochemistry.

[48]  Weidong Wang,et al.  Role of the mammalian SWI/SNF chromatin remodeling complex in the cellular response to UV damage , 2008, Cell cycle.

[49]  Yu Li,et al.  Genomic and functional evidence for an ARID1A tumor suppressor role , 2007, Genes, chromosomes & cancer.

[50]  A. Imbalzano,et al.  Mammalian SWI/SNF complexes facilitate DNA double‐strand break repair by promoting γ‐H2AX induction , 2006, The EMBO journal.

[51]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[52]  P. Dallas,et al.  Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors , 2004, International journal of cancer.

[53]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[54]  J. Lunceford,et al.  IFN-g – related mRNA profile predicts clinical response to PD-1 blockade , 2019 .

[55]  C. Roberts,et al.  ARID1A mutations in cancer: another epigenetic tumor suppressor? , 2013, Cancer discovery.